- Home
- SGLY vs VTAK Comparison
SGLY vs VTAK Comparison
Compare SGLY & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- VTAK
- Stock Information
- Founded
- SGLY 2001
- VTAK 2002
- Country
- SGLY United States
- VTAK United States
- Employees
- SGLY N/A
- VTAK N/A
- Industry
- SGLY
- VTAK Medical/Dental Instruments
- Sector
- SGLY
- VTAK Health Care
- Exchange
- SGLY Nasdaq
- VTAK Nasdaq
- Market Cap
- SGLY 3.4M
- VTAK 4.1M
- IPO Year
- SGLY 2008
- VTAK 2018
- Fundamental
- Price
- SGLY $0.63
- VTAK $2.46
- Analyst Decision
- SGLY
- VTAK
- Analyst Count
- SGLY 0
- VTAK 0
- Target Price
- SGLY N/A
- VTAK N/A
- AVG Volume (30 Days)
- SGLY 300.3K
- VTAK 397.9K
- Earning Date
- SGLY 11-14-2025
- VTAK 11-14-2025
- Dividend Yield
- SGLY N/A
- VTAK N/A
- EPS Growth
- SGLY N/A
- VTAK N/A
- EPS
- SGLY N/A
- VTAK N/A
- Revenue
- SGLY $1,813,193.00
- VTAK $600,000.00
- Revenue This Year
- SGLY N/A
- VTAK $822.86
- Revenue Next Year
- SGLY N/A
- VTAK $168.42
- P/E Ratio
- SGLY N/A
- VTAK N/A
- Revenue Growth
- SGLY N/A
- VTAK 37.62
- 52 Week Low
- SGLY $0.54
- VTAK $2.20
- 52 Week High
- SGLY $5.49
- VTAK $15.68
- Technical
- Relative Strength Index (RSI)
- SGLY 32.74
- VTAK 44.89
- Support Level
- SGLY $0.71
- VTAK $2.39
- Resistance Level
- SGLY $0.85
- VTAK $2.69
- Average True Range (ATR)
- SGLY 0.05
- VTAK 0.17
- MACD
- SGLY -0.00
- VTAK -0.04
- Stochastic Oscillator
- SGLY 3.45
- VTAK 12.02
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.